Scholar Rock Holding Corp. (SRRK) Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit.

“Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy” will be presented on January 28th, 2021 at 12:30 PM EST. The presentation will provide an overview of the preclinical data demonstrating selective inhibition of TGFβ1 activation with SRK-181-mIgG1 (murine version of SRK-181) induces combination treatment effects with anti-PD-1 on tumor growth in checkpoint inhibition therapy-resistant tumors as well as an improved preclinical toxicity profile compared to less selective TGFβ inhibition.

Scholar Rock will also be participating in a panel discussion titled “Debating the Best Approach to Target TGF-β” on January 27th, 2021 at 10:45 am EST.

You May Also Be Interested In

• Edgewise Therapeutics Inc. (EWTX) Granted EU Orphan Drug Designations for Sevasemten
• Legend Biotech (LEGN) Reports CARVYKTI Approved in EU
• Addus HomeCare (ADUS) Comments on Final Department of Health and Human Services Rule